Is it time to rethink checkpoint blockade therapy in non-Hodgkin lymphoma?

Beth Phillips; Timothy Illidge

doi:10.1111/bjh.16854

Is it time to rethink checkpoint blockade therapy in non-Hodgkin lymphoma?

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Commentary/debate › peer-review

Original language	English
Pages (from-to)	13-14
Number of pages	2
Journal	British Journal of Haematology\|B J H
Volume	191
Issue number	1
Early online date	18 Jun 2020
DOIs	https://doi.org/10.1111/bjh.16854
Publication status	Published - 1 Oct 2020

Keywords

checkpoint blockade therapy
malignancies
non-Hodgkin lymphoma

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/bjh.16854

Cite this

@article{bf191a30b421470bae1116d194471ca8,

title = "Is it time to rethink checkpoint blockade therapy in non-Hodgkin lymphoma?",

keywords = "checkpoint blockade therapy, malignancies, non-Hodgkin lymphoma",

author = "Beth Phillips and Timothy Illidge",

year = "2020",

month = oct,

day = "1",

doi = "10.1111/bjh.16854",

language = "English",

volume = "191",

pages = "13--14",

journal = "British Journal of Haematology|B J H",

issn = "0007-1048",